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INTRODUCTION
Lysophosphatidic acid (LPA) is a bioactive lipid that is concentrated in serum and is essential for a variety of cellular and developmental processes (reviewed in (Choi et al., 2010) ). While LPA does play a structural role in cell membranes, extracellular LPA is a highly selective and specific activator of a class of G protein-coupled receptors (GPCRs) called LPA receptors (LPARs) (reviewed in (Yung et al., 2014) ). There are currently six recognized LPARs, named LPA [1] [2] [3] [4] [5] [6] , with clear homologs between human (LPAR1-6) and mouse (Lpar1-6) genes (reviewed in ). All six receptors are expressed throughout the body during development and adulthood in unique spatiotemporal patterns. These receptors are involved in a variety of necessary functions, including cell survival, proliferation, migration, differentiation, vascular regulation, and cytokine release (reviewed in (Yung et al., 2014) ).
LPA can be produced in several ways through the activity of intracellular or extracellular enzymes. The two most prominent pathways involve the conversion of lysophosphatidyl choline (LPC) to LPA by autotaxin (ATX/Enpp2) (Tokumura et al., 2002; Umezu-Goto et al., 2002) and conversion of phosphatidic acid to LPA by phospholipase A1 or A2 (PLA1/PLA2) (Fourcade et al., 1995; Sonoda et al., 2002) . Intriguingly, ATX is highly expressed in blood, brain, kidney, the lymphatic system, and tissue surrounding injury (Bachner et al., 1999; Savaskan et al., 2007; Kanda et al., 2008) , suggesting important LPA-mediated mechanisms in these areas. Additionally, LPA is secreted by activated platelets and mature adipocytes (Eichholtz et al., 1993; Valet et al., 1998; Sano et al., 2002) . Because of its important roles throughout the body, aberrant LPA signaling has also been implicated in several diseases. This review focuses on the agents that have been developed to modulate LPA signaling and tested in disease models.
LYSOPHOSPHATIDIC ACID RECEPTOR SIGNALING
Interest in LPA as a signaling molecule dates back to the late 1970s when effects on intracellular calcium release, platelet aggregation, and blood pressure were reported (Tokumura et al., 1978; Gerrard et al., 1979) . While the involvement of G proteins was postulated (Moolenaar and van Corven, 1990) , the mechanism of LPA signaling was not elucidated until 1996 when the first LPA receptor was cloned (Hecht et al., 1996) . Since the discovery of LPA 1 (originally Vzg-1 or Edg-2), five
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other LPARs have been validated. LPA 2 and LPA 3 were elucidated through homology searches by comparing amino acid sequences to that of LPA 1 Bandoh et al., 1999) . Through efforts aimed at finding ligands for orphan receptors, LPA 4 and LPA 5 were discovered (Noguchi et al., 2003; Kotarsky et al., 2006; Lee et al., 2006) . Most recently, LPA 6 , a GPCR that is most closely related to LPA 4 , was added to the ranks of LPA receptors (Pasternack et al., 2008; Yanagida et al., 2009) . LPAR signaling occurs through a variety of intracellular cascades (reviewed in (Mirendil et al., 2013) ) (Fig. 1) . The binding of LPA or an LPA analog to its 7-transmembrane GPCR allows the G a subunit to exchange used GDP for GTP. This results in G a dissociating from G b and G γ , allowing the G a and G bγ complexes to signal through downstream effectors. Several G a subunits have been implicated in LPAR signaling, including G a12/13 , G aq/11 , G as , and G ai/O . Downstream effectors include activation of several pathways. The G a12/13 -mediated Rho/ROCK and Rho/SRF pathways have been implicated in cell motility, invasion, and cytoskeletal changes (Sotiropoulos et al., 1999; Kim and Adelstein, 2011; Jeong et al., 2012) . The G aq/11 pathway activates phospholipase C (PLC), which induces IP3, and subsequently initiates Ca 2+ and diacyl glycerol signaling (Sando and Chertihin, 1996) . This cascade can result in vasodilation and a variety of transcriptional changes, including protein kinase C-induced cell growth, immune recruitment, and changes in learning and memory (Lu et al., 1999; Seewald et al., 1999; Cummings et al., 2004; Ruisanchez et al., 2014) . Induction of the G as pathway leads to adenylyl cyclase (AC) activation and the production of cAMP, preventing cell migration (Jongsma et al., 2011) . Activation of G ai/O is the most versatile, as downstream effectors include PLC, Ras/MAPK-induced morphological changes (Kranenburg and Moolenaar, 2001 ), PI3K/Rac-mediated migration (Jimenez et al., 2000) , modula- www.biomolther.org tion of PI3K/Akt survival mechanisms (Kang et al., 2004; , and inhibition of AC. Each LPAR has multiple important regulatory functions th roughout the body (reviewed in (Yung et al., 2014) ). Many of these have been elucidated through the use of knockout animals, pharmacological LPAR agonists or antagonists, and gene association studies. The first discovered LPAR, LPA 1 , app ears to be responsible for several developmental, physiological, and pathological processes. These include cell survival, proliferation, adhesion, migration, immune function, and myelination (reviewed in (Fukushima et al., 2001) ). LPA 2 sig naling has also been implicated in cell survival, migration, immune function, and myelination (reviewed in (Ishii et al., 2004) ), often appearing to contribute to complementary LPA 1 mechanisms (Contos et al., 2002) . LPA 3 , while expressed in many different tissues, is most heavily characterized as being involved in reproduction; it mediates fertility, embryo spacing, and embryo implantation (Ye et al., 2005) . LPA 4 influences cell aggregation, cell adhesion, vascular development, and osteogenesis regulation (reviewed in (Mirendil et al., 2013) ). Additionally, LPA 4 -mediated adhesion appears to counteract LPA 1 / LPA 2 -stimulated migration processes . LPA 5 also negatively regulates cell motility and is involved in chemokine release (Jongsma et al., 2011; Lundequist and Boyce, 2011) . Although LPA 6 is the most recently discovered LPAR, several genome screening studies have been published linking mutations in LPA 6 to genetic hair loss and autosomal recessive hypotrichosis, or "wooly hair" syndrome (Azeem et al., 2008; Pasternack et al., 2008; Petukhova et al., 2008) . LPA 6 is also under investigation for further functionality. The effects of LPAR signaling are outlined in Figure 1 .
PHARMACOLOGICAL ADVANCES MODULATING LPA SIGNALING
As LPAR signaling has been strongly implicated in many disease states, great interest has been expressed in developing specific LPAR inhibitors. Currently, no LPA or LPARtargeting drugs have been FDA approved, though several are in development or undergoing clinical trials (Yung et al., 2014) (Table 1) . Furthermore, the ability to develop safe and efficacious drugs targeting lysophospholipid signaling has already been proven; fingolimod (FTY720), an analog of sphingosine 1-phosphate (S1P) and inhibitor of S1P receptors, has been FDA-approved for the treatment of multiple sclerosis (Brinkmann et al., 2002; Chun and Hartung, 2010; Calabresi et al., 2014) .
LPA signaling has long been implicated in immune reactions (reviewed in (Lin and Boyce, 2006) ). To this end, several therapeutic advances have been made concerning autoimmune disorders. In fact, an LPA 1/3 inhibitor, SAR100842, has completed phase II clinical trials to protect against systemic sclerosis (Sanofi, 2014) , an autoimmune disorder characterized by accumulated collagen in connective tissue, leading to scarring of the skin and vasculature (Lafyatis, 2014) . LPA 1 inhibitors are also of great interest in fibrosis, with BMS-986202 (previously AM152) having successfully completed phase I and BMS-986020 beginning phase II clinical trials for idiopathic pulmonary fibrosis (IPF) (2011, Amira Pharmaceuticals Announces Completion of Phase 1 Clnical Study for AM152, a Novel LPA1 Receptor Antagonist. In PR Newswire, PRNewswire.com. http://www.prnewswire.com/news-releases/ amira-pharmaceuticals-announces-completion-of-phase-1-clinical-study-for-am152-a-novel-lpa1-receptor-antagonist-121087874.html, Access Date: 2014/09/15; BMS, 2011 BMS, , 2014 . The LPA 1 inhibitor AM966 and the LPA 1/3 antagonist VPC12249 have also shown efficacy in murine IPF studies (Okusa et al., 2003; Swaney et al., 2010) . Concurrently, an LPA 3 agonist, oleoyl-methoxy phosphothionate (OMPT), enhanced IPF injury and reduced the therapeutic effects of VPC12249, suggesting that LPA 3 signaling may also be relevant in fibrotic disease. The pan-LPAR antagonist HLZ-56 and LPA 1 inhibitor AM095 attenuated kidney and dermal fibrosis in mouse models by preventing Smad2 phosphorylation, which reduced TGFb signaling and subsequent CTGF release (Castelino et al., 2011; Swaney et al., 2011; Geng et al., 2012) , a mechanism that may be central to LPAR inhibitor effectiveness in other fibrotic disorders.
Much of the enthusiasm for LPAR therapies is directed at cancer, as LPAR signaling has been shown in numerous studies to promote motility and invasion of several cancer types, including breast, ovarian, colon, and brain tumors Hama et al., 2004; Hoelzinger et al., 2008; Hayashi et al., 2012) . In vitro studies utilizing the pan LPAR/ATX antagonist a-bromomethylene phosphonate LPA (BrP-LPA) and LPA 1/3 antagonists Ki16425, Ki16198, and Debio 0719 have been shown to decrease tumor aggressiveness and increase radiosensitivity through varied mechanisms, including inhibited Rho/ROCK and MEK/ERK signaling, prevention of FAK/paxillin localization to focal adhesions, and reduced matrix metalloproteinase accumulation (Hama et al., 2004; Zhang et al., 2009; Komachi et al., 2012; Marshall et al., 2012; Schleicher et al., 2011; Liao et al., 2013; Su et al., 2013) . While many studies focus on the migratory effects of LPA 1 signaling, use of the LPA 2 inhibitor "compound 35" attenuated Erk phosphorylation and reduced proliferation of colorectal cancer cells (Beck et al., 2008) . LPA itself has been proposed as a screening molecule for ovarian cancer, as increased levels of LPA have been repeatedly observed in the blood of patients with malignant ovarian tumors and may have prognostic value in lung cancer patients as well (Sedlakova et al., 2011; Bai et al., 2014; NCI, 2014) . Although no LPAR-targeting cancer drugs have reached clinical trial stages thus far, pharmaceutical inquiry is progressing rapidly and the initiation of cancerfocused clinical trials is projected to follow.
In addition to cancer and fibrosis, LPAR inhibitors have been utilized as potential therapeutics in other areas of study. For instance, Ki16425 and BrP-LPA have been shown to decrease the clinical score of murine arthritis (Nikitopoulou et al., 2013; Orosa et al., 2014) . The development of an LPAinduced neonatal model of post-hemorrhagic hydrocephalus was also abrogated utilizing Ki16425 (Yung et al., 2011) . While LPA signaling is reported to be involved in wound-healing processes (Lee et al., 2000) , it may exacerbate severe trauma. In fact, anti-LPA antibodies that diminish LPAR binding and activation have shown some efficacy in modulating murine brain lesion severity and recovery (Goldshmit et al., 2012; Crack et al., 2014) , although the actual mechanism of these immunological agents remains to be determined. Additionally, BristolMyers Squibb has patented LPAR inhibitors for spinal cord injury and neuropathic pain indications (Nogueira and Vales, 2013) , since there is a substantial body of evidence implicating LPA 1 and LPA 5 signaling in the initiation and maintenance Cancer, rheumatoid arthritis, hydrocephalus (Hama et al., 2004; Liao et al., 2013; Orosa et al., 2014; Su et al., 2013; Yung et al., 2011) Debio 0719
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of neuropathic pain (reviewed in (Ueda et al., 2013) ).
The most common output for screening drug efficacy against an LPAR is determining the status of Ca 2+ influx within the tested cell types. Generally, LPAR agonists will increase intracellular Ca 2+ mobilization while LPAR antagonists will inhibit Ca 2+ release. Using this method, several studies have been pu blished on the synthesis and relative efficacy of potential therapeutics against LPA 1-3 , LPA 1-5 , and more recently LPA 1-6 (reviewed in (Im, 2010) ). While this article only discusses pharmacological modulators with functional, disease-related readouts, a more comprehensive list of LPAR agonists and antagonists can be found in a previous review (Yung et al., 2014) .
COMPOUNDS TARGETING ATX INHIBITION
In addition to direct pharmacological modulation of LPARs, several research groups have targeted the upstream enzyme ATX for discovery of potential therapeutics (Table 1) . ATX inhibitors prevent the enzymatic conversion of LPC to LPA. As ATX expression can account for at least half of plasma LPA levels (Tanaka et al., 2006; van Meeteren et al., 2006) , these drugs ultimately attenuate LPA signaling. Although this pathway lies upstream of LPAR signaling, targeting ATX allows for structure-based drug design (Fells et al., 2013; Kawaguchi et al., 2013; Norman et al., 2013) , a process that is limited in LPAR drug discovery because of the lack of receptor crystal structures; work in progress should rectify this deficiency.
In particular, oncology researchers are interested in developing these agents. Several ATX inhibitors have been synthesized and tested in tumor migration, metastasis, survival, and radiosensitivity studies. These inhibitors include the small molecules ONO-8430506 (Benesch et al., 2014) and PF-8380 (Bhave et al., 2013; St-Coeur et al., 2013) , lipid analogs 4PBPA (Gupte et al., 2011) and pan-ATX/LPAR antagonist BrP-LPA (Xu and Prestwich, 2010; Schleicher et al., 2011) , and gintonin -a plant-derived LPA/ginseng glycolipoprotein complex that results in feedback inhibition of ATX through LPAR signaling (Hwang et al., 2013) . These compounds ultimately reduced survival and invasive behaviors of in vitro cancer cells and tumor xenografts. As ATX and LPARs are often upregulated in cancer (reviewed in (Gotoh et al., 2012) ), the success of these compounds in research may spur therapeutic development.
ATX antagonism is also being investigated as a solution to inflammatory disease. PF-8380 has been shown to drastically reduce plasma LPA concentrations during inflammation (Gierse et al., 2010) , suggesting that targeting ATX may be useful to reduce chronic inflammation. As mentioned above, BrP-LPA has been utilized to ameliorate arthritis in mice (Nikitopoulou et al., 2013) . Furthermore, GWJ-A-23 showed efficacy in attenuating allergen-induced asthmatic attacks and bleomycin-induced IPF (Oikonomou et al., 2012; Park et al., 2013) . The effects of reduced LPA signaling stretch even further, as the potent ATX inhibitor S32826 has been utilized to decrease intraocular pressure in a rabbit model of glaucoma (Iyer et al., 2012) .
CONCLUSION
Over the past four decades, interest in the signaling lipid LPA has grown from understanding its synthesis to encompassing several key processes in development and disease. To this end, several compounds have been fine-tuned by researchers and pharmaceutical companies to inhibit LPARs and ATX in order to mitigate the destructive pathologies related to cancer, autoimmune diseases, and other afflictions. The LPA 1 -targeting inhibitors SAR100842, BMS-986202, and BMS-986020 have passed phase I or phase II clinical trials with the potential of advancing toward FDA approval. The increasing availability of chemical tool compounds will enhance our understanding of LPAR signaling mechanisms in disease towards the development of new disease-modifying therapeutics.
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